| Literature DB >> 35965851 |
Mahdawi Joya1, Ahmad Khalid Aalemi2, Abdul Tawab Baryali3.
Abstract
Background: Urinary tract infections (UTIs) are the most prevalent infections, with a variety of etiologic agents, a high number of occurrences, relapses, and complications; also, antibiotic resistance of the pathogenic bacterium is a hugely significant challenge for physicians. Objective: The goal of this research was to identify the common bacterial uropathogens as well as their susceptibility to commonly used antibiotics. Materials andEntities:
Keywords: UTI; antibiotic; bacterial; prevalence; susceptibility; uropathogen
Year: 2022 PMID: 35965851 PMCID: PMC9365322 DOI: 10.2147/IDR.S353818
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Distribution of Patients in FMIC in the First Six Months of 2018 According to Uropathogenic Status by Sex
| Uropathogenic Status | Male | Female | Total | |||
|---|---|---|---|---|---|---|
| n | % | n | % | N | % | |
| Non-uropathogenic | 440 | 30.58 | 999 | 69.42 | 1439 | 80.85 |
| Uropathogenic | 102 | 29.9 | 239 | 70.1 | 341 | 19.15 |
| Total | 542 | 30.4 | 1238 | 69.6 | 1780 | 100.0 |
Figure 1Distribution of microorganisms in positive samples of urine at the French Medical Institute for Children.
Antibiotic Resistance of UTI Isolated Bacteria at the French Medical Institute for Children
| Antibiotics | Uropathogenic Isolated Bacteria and Resistance Rate to Antibiotics | ||||||
|---|---|---|---|---|---|---|---|
| Ceftriaxone (N=272) | 165(77.4%) | 4(40.0%) | 0(0.0%) | 21(65.6%) | 1(20.0%) | 1(100%) | 5(50%) |
| Amoxicillin (N=281) | 182(84.2%) | 8(80%) | 0(0.0%) | 28(77.7%) | 5(83.3%) | 4(100%) | 6(75.0%) |
| Ceftazidime (N=269) | 163(77.9%) | 1(33.3%) | 0(0.0%) | 21(56.7%) | 2(33.3%) | 4(100%) | 4(50%) |
| Aztreonam (N=127) | 55(56.7%) | 0(0.0%) | 0(0.0%) | 9(42.8%) | 1(50%) | 1(50%) | 1(33.3%) |
| Ciprofloxacin (N=243) | 114(70.8%) | 22(75.8%) | 8(36.3%) | 11(57.8%) | 0(0.0%) | 2(100%) | 2(33.3%) |
| Cefixime (N=51) | 34(87.1%) | 0(0.0%) | 2(100%) | 2(50.0%) | – | – | 1(20.0%) |
| Sulfamethoxazole (N=186) | 97(81.5%) | 15(57.6%) | 12(80.0%) | 10(71.4%) | 2(50%) | 1(100%) | 2(28.5%) |
| Ertapenem (N=12) | 0(0.0%) | – | – | – | – | – | 1(25%) |
| Imipenem (N=115) | 1(1.1%) | 0(0.0%) | 0(0.0%) | 1(5.2%) | 0(0.0%) | 1(33.3%) | 0(0.0%) |
| Amikacin (N=330) | 6(2.7%) | 21(65.6%) | 0(0.0%) | 3(8.1%) | 0(0.0%) | 1(25%) | 0(0.0%) |
| Tazobactam (N=276) | 7(3.2%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(16.6%) | 1(33.3%) | 0(0.0%) |
| Fosfomycin (N=246) | 7(3.8%) | 4(28.5%) | 0(0.0%) | 0(0.0%) | 3(50.0%) | 2(100%) | 1(11.1%) |
| Ampicillin (N=284) | 202(93.9%) | 6(60.0%) | 4(80.0%) | 35(97.2%) | 5(100%) | 4(100%) | 7(77.7%) |
| Gentamicin (N=330) | 69(33.8%) | 23(71.8%) | 6(22.2%) | 12(37.5%) | 1(16.6%) | 1(25%) | 4(44.4%) |
| Pristinamycin (N=3) | – | 0(0.0%) | – | – | – | – | – |
| Fusidic acid (N=51) | – | 4(16%) | 5(19.2%) | – | – | – | – |
| Clindamycin (N=52) | 1(100%) | 12(42.8%) | 2(8.6%) | – | – | – | – |
| Rifampicin (N=52) | – | 5(19.2%) | 0(0.0%) | – | – | – | – |
| Ticarcillin (N=5) | – | 0(0.0%) | 0(0.0%) | – | – | – | – |
| Vancomycin (N=40) | 0(0.0%) | 1(100%) | 0(0.0%) | – | – | – | – |
| Penicillin (N=43) | – | 10(47.6%) | 13(59.0%) | – | – | – | – |
| Cefoxitin (N=29) | – | 5(55.5%) | 1(5%) | – | – | – | – |
| Erythromycin (N=56) | 2(66.6%) | 26(81.2%) | 18(75%) | – | – | – | – |
| Nitrofurantoin (N=244) | 16(8.2%) | 1(14.2%) | 0(0.0%) | 1(3.7%) | 2(40%) | – | 2(28.5%) |
Note: – means that this bacteria did not test for that antibiotic.
Figure 2Total resistance rate in UTI isolated bacteria at the French Medical Institute for Children.